Axura

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

memantin hidroklorid

Available from:

Merz Pharmaceuticals GmbH

ATC code:

N06DX01

INN (International Name):

memantine

Therapeutic group:

Ostali lijekovi protiv demencije

Therapeutic area:

Alzheimerova bolest

Therapeutic indications:

Liječenje bolesnika s umjerenom ili teškom Alzheimerovom bolesti.

Product summary:

Revision: 27

Authorization status:

odobren

Authorization date:

2002-05-17

Patient Information leaflet

                                52
B. UPUTA O LIJEKU
53
UPUTA O LIJEKU: INFORMACIJA ZA KORISNIKA
AXURA 10 MG FILMOM OBLOŽENE TABLETE
memantinklorid
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovo pročitati.
-
Ako imate dodatnih pitanja, obratite se svom liječniku ili
ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI
1.
Što je Axura i za što se koristi
2.
Što morate znati prije nego počnete uzimati Axuru
3.
Kako uzimati Axuru
4.
Moguće nuspojave
5.
Kako čuvati Axuru
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE AXURA I ZA ŠTO SE KORISTI
KAKO DJELUJE AXURA
Axura sadrži djelatnu tvar memantinklorid.
Axura se ubraja u skupinu lijekova poznatih kao lijekovi protiv
demencije.
Gubitak pamćenja u Alzheimerovoj bolesti pripisuje se poremećaju
prijenosa signala u mozgu. Mozak
sadržava takozvane N-metil-D-aspartat (NMDA) receptore koji su
uključeni u prijenos živčanih signala
važnih u učenju i pamćenju. Axura spada u skupinu lijekova poznatih
kao antagonisti NMDA receptora.
Axura djeluje na navedene NMDA receptore poboljšavajući prijenos
živčanih signala i pamćenje.
ZA ŠTO SE AXURA KORISTI
Axura se koristi za liječenje bolesnika s umjerenom do teškom
Alzheimerovom bolešću.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE UZIMATI AXURU
NEMOJTE UZIMATI AXURU
-
ako ste alergični (preosjetljivi) na memantinklorid ili neki drugi
sastojak Axura tableta (naveden
u dijelu 6).
UPOZORENJA I MJERE OPREZA
Obratite se svom liječniku ili ljekarniku prije nego uzmete Axuru
-
ako u anamnezi imate epileptičke napadaje
-
ako ste nedavno imali infarkt miokarda (srčani udar), ili ako
bolujete od kongestivnog zatajenja
srca il
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Axura 10 mg filmom obložene tablete
Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete
Axura 20 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Axura 10 mg filmom obložene tablete
Svaka filmom obložena tableta sadrži 10 mg memantinklorida, što
odgovara 8,31 mg memantina.
Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete
Svaka filmom obložena tableta sadrži 5 mg memantinklorida, što
odgovara 4,15 mg memantina.
Svaka filmom obložena tableta sadrži 10 mg memantinklorida, što
odgovara 8,31 mg memantina.
Svaka filmom obložena tableta sadrži 15 mg memantinklorida, što
odgovara 12,46 mg memantina.
Svaka filmom obložena tableta sadrži 20 mg memantinklorida, što
odgovara 16,62 mg memantina.
Axura 20 mg filmom obložene tablete
Svaka filmom obložena tableta sadrži 20 mg memantinklorida, što
odgovara 16,62 mg memantina.
Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložene tablete.
Axura 10 mg filmom obložene tablete
Blijedožuta do žuta filmom obložena tableta ovalnog oblika, s
razdjelnom crtom i utisnutim oznakama
“1-0” na jednoj strani i “M M” na drugoj strani.
Tableta se može razdijeliti na jednake doze.
Axura 5 mg+10 mg+15 mg+20 mg filmom obložene tablete
Filmom obložene tablete od 5 mg su bijele do gotovo bijele, ovalno
duguljaste filmom obložene tablete
s utisnutom oznakom ‘5’ na jednoj strani i ‘MEM’ na drugoj
strani.
Filmom obložene tablete od 10 mg su blijedožute do žute, filmom
obložene tablete ovalnog oblika, s
razdjelnom crtom i utisnutom oznakom “1-0” na jednoj strani i “M
M” na drugoj strani. Tableta se
može razdijeliti na jednake polovice.
Filmom obložene tablete od 15 mg su narančaste do sivo-narančaste,
ovalno duguljaste filmom
obložene tablete s utisnutom oznakom ‘15’ na jednoj strani i
‘MEM’ na drugoj strani.
Filmom obložene tablete od 20 mg su blijedocrvene do sivo-crvene,
ovalno duguljaste filmom obložene
tabl
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 26-02-2024
Public Assessment Report Public Assessment Report Bulgarian 05-01-2012
Patient Information leaflet Patient Information leaflet Spanish 26-02-2024
Public Assessment Report Public Assessment Report Spanish 05-01-2012
Patient Information leaflet Patient Information leaflet Czech 26-02-2024
Public Assessment Report Public Assessment Report Czech 05-01-2012
Patient Information leaflet Patient Information leaflet Danish 26-02-2024
Public Assessment Report Public Assessment Report Danish 05-01-2012
Patient Information leaflet Patient Information leaflet German 26-02-2024
Public Assessment Report Public Assessment Report German 05-01-2012
Patient Information leaflet Patient Information leaflet Estonian 26-02-2024
Public Assessment Report Public Assessment Report Estonian 05-01-2012
Patient Information leaflet Patient Information leaflet Greek 26-02-2024
Public Assessment Report Public Assessment Report Greek 05-01-2012
Patient Information leaflet Patient Information leaflet English 26-02-2024
Public Assessment Report Public Assessment Report English 05-01-2012
Patient Information leaflet Patient Information leaflet French 26-02-2024
Public Assessment Report Public Assessment Report French 05-01-2012
Patient Information leaflet Patient Information leaflet Italian 26-02-2024
Public Assessment Report Public Assessment Report Italian 05-01-2012
Patient Information leaflet Patient Information leaflet Latvian 26-02-2024
Public Assessment Report Public Assessment Report Latvian 05-01-2012
Patient Information leaflet Patient Information leaflet Lithuanian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 26-02-2024
Public Assessment Report Public Assessment Report Lithuanian 05-01-2012
Patient Information leaflet Patient Information leaflet Hungarian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 26-02-2024
Public Assessment Report Public Assessment Report Hungarian 05-01-2012
Patient Information leaflet Patient Information leaflet Maltese 26-02-2024
Public Assessment Report Public Assessment Report Maltese 05-01-2012
Patient Information leaflet Patient Information leaflet Dutch 26-02-2024
Public Assessment Report Public Assessment Report Dutch 05-01-2012
Patient Information leaflet Patient Information leaflet Polish 26-02-2024
Public Assessment Report Public Assessment Report Polish 05-01-2012
Patient Information leaflet Patient Information leaflet Portuguese 26-02-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 26-02-2024
Public Assessment Report Public Assessment Report Portuguese 05-01-2012
Patient Information leaflet Patient Information leaflet Romanian 26-02-2024
Public Assessment Report Public Assessment Report Romanian 05-01-2012
Patient Information leaflet Patient Information leaflet Slovak 26-02-2024
Public Assessment Report Public Assessment Report Slovak 05-01-2012
Patient Information leaflet Patient Information leaflet Slovenian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 26-02-2024
Public Assessment Report Public Assessment Report Slovenian 05-01-2012
Patient Information leaflet Patient Information leaflet Finnish 26-02-2024
Public Assessment Report Public Assessment Report Finnish 05-01-2012
Patient Information leaflet Patient Information leaflet Swedish 26-02-2024
Public Assessment Report Public Assessment Report Swedish 05-01-2012
Patient Information leaflet Patient Information leaflet Norwegian 26-02-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 26-02-2024
Patient Information leaflet Patient Information leaflet Icelandic 26-02-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 26-02-2024

Search alerts related to this product

View documents history